EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy programme for epilepsy ahead of first-in-human trial
Collaboration with AAV-specialist CDMO will support scalable production of EPY201 for focal refractory epilepsy affecting 10 million people LONDON and SAN SEBASTIÁN, Spain, Sept. 9, 2026 /PRNewswire/ — EpilepsyGTx, a biotechnology company
